Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821794 | 0.81 | OPRM1 (0.39) | NR1H4ALDH1A1S1PR1ACHECHRM2 | |
| SCHEMBL3059109 | 0.80 | ACHE (0.39) | SLC6A2SLC6A4SLC6A3S1PR1ACHE | |
| SCHEMBL8170417 | 0.80 | CNR2 (0.55) | SCN4ACNR2CNR1 | |
| Hydrochloric Acid SCHEMBL3064216 | 0.79 | ACHE (0.39) | SLC6A2SLC6A4SLC6A3S1PR1ACHE | |
| SCHEMBL3819363 | 0.79 | ATM (0.39) | NR1H4SLC6A2SLC6A3S1PR1ACHE | |
| SCHEMBL3064159 | 0.79 | CHRM1 (0.42) | NR1H4ACHECHRM2CHRM1CHRM3 | |
| SCHEMBL3053871 | 0.78 | CNR2 (0.41) | NR1H4CNR2CNR1CHRM2CHRM1 | |
| SCHEMBL4734946 | 0.78 | LMNA (0.58) | ALDH1A1 | |
| SCHEMBL4738981 | 0.77 | LMNA (0.41) | NR1H4S1PR1ACHECHRM2CHRM1 | |
| SCHEMBL3067558 | 0.77 | ENPP2 (0.36) | SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | claimed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | SCN4A 94/4885NR1H4 761/4885SLC6A2 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.